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Potential neurovirulence of common cold virus
An elegant recent study by Thomas Dufresne and Matthias
Gromeier1 suggests that a causative agent of the common
cold, coxsackievirus A21 (CAV21), is potentially neuroviru-
lent and could, under the right circumstances, cause a
poliomyelitis-like illness. CAV21 and poliovirus are mem-
bers of the enterovirus genus (family Picornaviridae) and
show remarkable genetic similarity.2 However, CAV21
causes upper respiratory-tract infections whereas poliovirus
causes neurological disease including poliomyelitis, which
clinically manifests as acute ﬂaccid paralysis. The contrast in
clinical presentation has been attributed to the different
receptors used for cell invasion: intercellular adhesion
molecule-1 (ICAM-1) is the receptor for CAV21 and CD155
is the receptor for poliovirus. Not surprisingly, the genomes
of these two related viruses show the greatest dissimilarity
in the capsid (or viral coat) region.3
Murine ICAM-1 does not support CAV21 binding and mice
are not normally susceptible to infection with this virus.
Dufresne and Gromeier1 stably inserted the gene encoding
human ICAM-1 (hICAM-1) into the genome of a mouse
(which thus became transgenic), resulting in expression of
hICAM-1 by the animal’s cells. They then inoculated one
gastrocnemius muscle of the transgenic mouse with CAV21.
Acute ﬂaccid paralysis developed in the injected muscle, but
not in any other muscle. CAV21 replication, motorneuron
destruction, and inﬂammation were detected in the ipsilat-
eral anterior horn of the spinal cord, but viral replication was
not seen in the injected muscle. The abnormalities in the
spinal cord did not occur if the sciatic nerve was transected
before inoculation (ﬁgure). These observations suggest that
CAV21 can be pathogenic for motorneurons and that this
neurovirulence is dependent on invasion of the central
nervous system by retrograde transport along nerve axons.
These ﬁndings are scientiﬁcally important because they
suggest that CAV21 has all the machinery required to cause
a poliomyelitis-like illness, but is prevented from doing so by
virtue of its receptor not being expressed at the neuromus-
cular junction. Dufresne and Gromeier1 found low levels of
hICAM-1 at the neuromuscular junction of hICAM-1 trans-
genic mice, but not in wild-type mice. Unfortunately, they
did not report whether there is hICAM-1 expression at the
human neuromuscular junction, so leaving doubt as to how
the observations translate to human beings. They also
found hICAM-1 expression on motorneurons in the spinal
cord of transgenic mice, but no paralysis occurred when
CAV21 was injected directly into the central nervous system.
This apparently paradoxical observation could be explained
by a requirement for neuronal infection of a co-receptor that
is expressed at the neuromuscular junction, but not by neu-
rons in the central nervous system. A role has been found for
decay accelerating factor as a coreceptor for CAV21 attach-
ment to human cell lines4 and, indeed, decay accelerating
factor is expressed at the neuromuscular junction,5 but could
not be found on neurons in the central nervous system.6
2004 sees the 50th anniversary of Enders, Weller, and
Robbins receiving the Nobel Prize in Medicine for culturing
poliovirus,7 and the year coincides with the ﬁnal stages of
the Global Polio Eradication Programme. How clinically sig-
niﬁcant is the discovery of neurovirulent potential for
CAV21 from a public-health perspective and should it con-
cern us? Dufresne and Gromeier1 chose to refer to the acute
ﬂaccid paralysis observed with CAV21 infection in hICAM-
1-transgenic mice as “poliomyelitis”. In line with WHO def-
initions, we think this term is best reserved for poliovirus
and that “poliomyelitis-like illness” should be used for acute
ﬂaccid paralysis caused by other agents.8 Thus poliomyelitis
eradication is not directly affected by Dufresne and
Gromeier’s ﬁndings, but their results increase our concern
that the global public-health burden of acute ﬂaccid paral-
ysis will not disappear with the eradication of poliovirus.
Several reasons suggest that CAV21 itself is unlikely to be
a clinically signiﬁcant cause of poliomyelitis-like illness in
human beings. CAV21 infection in the hICAM-1 transgenic
mice is site-restricted and much less aggressive than
poliomyelitis in human beings. Paralysis only occurred in
the hICAM-1 transgenic mice via the intramuscular route
and not with intravenous, intranasal, or central nervous
system routes, and paralysis remained localised to the
injected muscle. This observation is analogous to “provoca-
tion poliomyelitis” where skeletal muscle injury predisposes
an individual to poliomyelitis from concurrent poliovirus
infection.9 Unlike CAV21 in hICAM-1 transgenic mice,
poliovirus can spread to the central nervous system directly
in the context of viraemia, as well as via retrograde axonal
transport. In addition, poliovirus usually enters human
beings via the oral route and not by the direct intramuscular
route. Dufresne and Gromeier1 did not report the result of
oral administration of CAV21 in hICAM-1 transgenic mice.
What could account for the difference in severity between
CAV21-induced poliomyelitis-like illness and poliomyelitis?
The most likely answer is differences in binding of viral capsid
with either hICAM-1 or CD155 and the tissue distribution of
these receptors and any relevant co-receptors, such as decay
accelerating factor. CAV21 could present more of a threat to
10 Llovet JM, Wurmbach E. Gene expression proﬁles in hepatocellular carci-
noma: not yet there. J Hepatol 2004; 41: 336–39.
11 Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression
proﬁles between hepatitis B virus- and hepatitis C virus-infected 
hepatocellular carcinoma by oligonucleotide microarray data on the basis
of a supervised learning method. Cancer Res 2002; 62: 3939–44.
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human beings if it successfully switched its receptor speci-
ﬁcity from hICAM-1 to CD155 and developed into a new
polio-like virus. How likely is this? It has been suggested that
this process would be more likely in the face of poliovirus
eradication.10 RNA viruses such as the enteroviruses have
extremely high mutation frequencies and exist as a mixture
of slightly different viruses or quasispecies, allowing rapid
evolution.11 Nevertheless, wild-type poliovirus has been
absent from many countries for years and no obvious
replacement of poliovirus with CAV21 has emerged.
It is important to appreciate that various viruses are recog-
nised causes of poliomyelitis-like illness, including ﬂaviviruses
such as Japanese encephalitis and West Nile virus.8 Several
enteroviruses can cause poliomyelitis-like illness, and so it is
possible that CAV21 occasionally causes a poliomyelitis-like
illness, although this has never been described. To a certain
extent, human enterovirus 71 has already made a bid to
occupy the biological niche vacated by poliovirus. Human
enterovirus 71, which is thought to enter cells via the receptor
for neuron growth factor,12 causes neurological disease,
including poliomyelitis-like illness, as well as hand-foot-and-
mouth disease. Although ﬁrst discovered in 1969, there has
been a signiﬁcant increase in epidemic activity for human
enterovirus 71 in the Asia-Paciﬁc region since 1997, with out-
breaks in Malaysia, Taiwan, Singapore, and Australia.13
The neurovirulent potential of CAV21 seen by Dufresne
and Gromeier1 using a mouse transgenic for hICAM-1 is an
interesting scientiﬁc ﬁnding and sheds new light on the
pathogenesis of viral infections in the nervous system. At
present, it seems unlikely that CAV21 will present a major
threat to public health.
*Calman MacLennan, Tom Solomon
Malawi-Liverpool-Wellcome Trust Clinical Research Programme,
College of Medicine, PO Box 30096, Blantyre 3, Malawi; and MRC
Centre for Immune Regulation, University of Birmingham,
Birmingham, UK (CM); Departments of Neurological Science and
Medical Microbiology, University of Liverpool, Liverpool, UK (TS) 
cmaclennan@mlw.medcol.mw
CM is a Wellcome Trust Training Fellow in Clinical Tropical Medicine, and TS IS A
Wellcome Trust Career Development Fellow. We declare that we have no conﬂict
of interest.
1 Dufresne AT, Gromeier M. A nonpolio enterovirus with respiratory tropism
causes poliomyelitis in intercellular adhesion molecule-1 transgenic mice.
Proc Natl Acad Sci USA 2004; 101: 13636–41.
2 Pulli T, Koskimies P, Hyypia T. Molecular comparision of coxsackie A virus
serotypes. Virology 1995; 212: 30–38.
3 Brown B, Oberste S, Maher K, Pallansch MA. Complete genomic
sequencing shows that polioviruses and members of human enterovirus
species C are closely related in the noncapsid coding region. J Virol 2003;
77: 8973–84.
4 Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. Coxsackie A21
binds to decay-accelerating factor but requires intercellular adhesion mole-
cule 1 for cell entry. J Virol 1997; 71: 4736–43.
5 Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME. Complement regulators
in extraocular muscle and experimental autoimmune myasthenia gravis.
Exp Neurol 2004; 189: 333–42.
6 Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. Differential
expression of individual complement regulators in the brain and choroid
plexus. Lab Invest 1999; 79: 1247–59.
7 Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of
poliomyelitis virus in cultures of various human embryonic tissues. Science
1949; 109: 85–87.
8 Solomon T, Willison H. Infectious causes of acute ﬂaccid paralysis.
Curr Opin Infect Dis 2003; 16: 375–81.
9 Gromeier M, Wimmer E. Mechanism of injury-provoked poliomyelitis.
J Virol 1998; 72: 5056–60.
10 Rieder E, Gorbalenya AE, Xaio C, et al. Will the polio niche remain vacant?
Dev Biol (Basel) 2001; 105: 111–22.
11 De la Torre JC, Giachetti C, Semler BL, Holland JJ. High frequency of single-
base transitions and extreme frequency of precise multiple-base reversion
mutations in poliovirus. Proc Natl Acad Sci USA 1992; 89: 2531–35.
12 Wen YY, Chang TY, Chen ST, Li C, Liu HS. Comparative study of
enterovirus 71 infection of human cell lines. J Med Virol 2003; 70: 109–18.
13 McMinn PC. An overview of the evolution of enterovirus 71 and its clinical
and public health signiﬁcance. FEMS Microbiol Rev 2002; 26; 91–107.
A
B
C
Retrograde transportation of CAV21
hICAM-1
No viral replication or
motorneuron destruction
Viral replication and
motorneuron destruction + Paralysis
No viral replication or
motorneuron destruction
Neuromuscular
junction
Motorneuron
axon
Anterior horn
of spinal cord
Wild-type mouse motorneuron
hICAM-1 transgenic mouse motorneuron
hICAM-1 transgenic mouse motorneuron
Transection of
sciatic nerve
Figure: Motorneuron innervating gastrocnemius muscle in three mice from experiments by Dufresne and
Gromeier1
Strokes and holes and headaches: are they a package deal?
The relation between patent foramen ovale (PFO) and
systemic embolisation, especially transient ischaemic
attack or stroke, has attracted considerable interest over the
past decades1 because of the increasingly widespread appli-
cation of diagnostic echocardiography and now transcranial
doppler ultrasound. The possibility that a young woman
had a clot pass through a PFO and cause a fatal stroke was
suggested in 1877.2 In 1881, Zahn reported systemic
embolisation through a PFO in a woman with uterine
thrombi;3 he added “paradoxical embolism” to the medical
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